Adverse drug reactions in the era of COVID-19COVID-19 시대의 약물 부작용Comment Published on 2021-04-012022-09-11 Journal: Internal and Emergency Medicine [Category] MERS, SARS, 치료제, [키워드] Adverse drug reaction COVID-19 [DOI] 10.1007/s11739-020-02603-w PMC 바로가기 [Article Type] Comment
Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions-replySARS-CoV-2 입원 환자의 약물이상반응: 약물-약물 상호작용을 중심으로 한 사례 시리즈-답변Comment Published on 2021-04-012022-09-11 Journal: Internal and Emergency Medicine [Category] MERS, SARS, 치료제, [키워드] Adverse drug reaction hospitalised SARS-CoV-2 [DOI] 10.1007/s11739-021-02677-0 PMC 바로가기 [Article Type] Comment
Adverse drug reactions in SARS-COV-2 hospitalised patients: a case series with a focus on drug-drug interactions-commentSARS-COV-2 입원 환자의 약물이상반응: 약물-약물 상호작용을 중심으로 한 사례 시리즈-코멘트Comment Published on 2021-04-012022-09-11 Journal: Internal and Emergency Medicine [Category] MERS, SARS, 치료제, [키워드] Adverse drug reaction case sery hospitalised [DOI] 10.1007/s11739-021-02645-8 PMC 바로가기 [Article Type] Comment
French Pharmacovigilance Public System and COVID-19 Pandemic프랑스 약물감시 공공 시스템 및 COVID-19 팬데믹Article Published on 2021-04-012022-09-11 Journal: Drug safety [Category] SARS, 치료제, [키워드] activity Adverse drug reaction Analysis candidate Case report case reports Clinicians COVID-19 COVID-19 pandemic drug reaction effective exceptional feedback French Health Health crisis healthcare heart identify kidney Medicine Multi-organ damage pandemic pharmacological pharmacovigilance Public System Timeliness transmitted unique [DOI] 10.1007/s40264-020-01034-y PMC 바로가기 [Article Type] Article
Patient characterization and adverse health care-related events in SARS-CoV-2 infected patients who died in a tertiary hospital3차 병원에서 사망한 SARS-CoV-2 감염 환자의 환자 특성 및 의료 관련 부작용Observational Study Published on 2021-03-262022-09-11 Journal: Medicina clínica [Category] 임상, 치료제, [키워드] Adverse Adverse drug reaction Adverse drug reactions adverse event adverse events Case fatality rate center close monitoring Comorbidity COVID-19 died drug reaction eight Episodios adversos event Fatality rate Frequency Health hospital Infection intensive care units management mechanical ventilation median age medical record Mortalidad Mortality observational study Pandemia pandemic Patient patients with SARS-CoV-2 problem problems RAM Reactions retrospective SARS-CoV-2 SARS-CoV-2 infected patient SARS-COV-2 infection study period the disease therapeutic [DOI] 10.1016/j.medcli.2020.11.002 PMC 바로가기 [Article Type] Observational Study
Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States미국에서 유행성 타임라인이 시작될 때 COVID-19에 대한 약물 요법의 사용 및 안전성에 대한 다기관 점 유병률 평가Multicenter Study Published on 2021-03-182022-09-11 Journal: American journal of health-system pharmacy : AJHP [Category] SARS, 치료제, [키워드] addition ADR ADRS Adverse drug reaction Adverse drug reactions Adverse reaction Adverse reactions antagonist Asthma Characteristics clinical Clinical data clinical trial clinical trials combination therapy Community Comprehensive conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 treatments drug reaction drug therapy enrolled evaluated hospital Hydroxychloroquine identify interleukin interleukin-6 lAbel medication medication safety medications mitigate Most patient Most patients multicenter observational study occurred Odds ratio off-label pandemic Patient patients patients hospitalized patients treated patients with COVID-19 point prevalence Prevalence prevalence study random Random sample receiving Remdesivir SARS-CoV-2 supported supportive care the United State Therapies therapy treated Treatment while [DOI] 10.1093/ajhp/zxaa426 PMC 바로가기 [Article Type] Multicenter Study
Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment MethodOriginal Research Published on 2021-02-052023-08-30 Journal: Frontiers in Pharmacology [Category] E형 간염, [키워드] Adverse drug reaction clinical pharmacology Drug-induced liver injury elderly pharmacovigilance Roussel Uclaf Causality Assessment Method [DOI] 10.3389/fphar.2020.600255 PMC 바로가기 [Article Type] Original Research
Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problemCOVID-19에서 로피나비르/리토나비르에 의해 유발된 자발적인 보고된 심장독성. 과거에 해결된 문제Article Published on 2021-02-012022-09-11 Journal: International journal of cardiology [Category] 신약개발, 치료제, [키워드] Adverse drug reaction Adverse drug reactions Adverse reaction Adverse reactions analyzed antiretroviral drug arrhythmia average baseline Bundle branch bundle branch block cardiac Cardiac arrhythmia Cardiotoxicity caution center Characteristics characterized collected conduction Conduction disorder COVID-19 COVID-19 pandemic drug combination drug-related side effects and adverse reactions ECGs functions hospital incidence Long Long QT syndrome Lopinavir Lopinavir-ritonavir Lopinavir-ritonavir drug combination. Lopinavir/ritonavir MOST National network offer Other pharmacovigilance Potassium potassium channel QTc QTC prolongation reflected Regional reported risk Ritonavir Side effect sodium Spontaneous syndrome Treatment treatment of COVID-19 ventricular ventricular arrhythmias [DOI] 10.1016/j.ijcard.2020.10.028 PMC 바로가기 [Article Type] Article
Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 PatientsCOVID-19 환자에서 로피나비르/리토나비르의 혈장 농도 및 안전성Article Published on 2021-02-012022-09-11 Journal: Therapeutic drug monitoring [Category] 치료제, [키워드] absence Adverse drug reaction Adverse drug reactions antiviral activity average caution Concentration COVID-19 COVID-19 patient disorders dosage drug reaction Efficacy expected HIV HIV treatment in vivo increase in Inflammation Inflammatory interquartile lAbel limit Lopinavir Lopinavir/ritonavir moderate-to-severe COVID-19 Occurrence off-label off-label use one patient Patient plasma concentration plasma concentrations Previous studies reduced reported required Retrospective study Ritonavir Safety safety profile SARS-CoV-2 significantly suggested treated Treatment treatment for COVID-19 [DOI] 10.1097/FTD.0000000000000838 PMC 바로가기 [Article Type] Article
The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-01-042022-09-10 Journal: Trials [Category] 임상, 치료제, [키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight [DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter